Secondary analysis of an RCT of metformin vs placebo in 785 pregnant women with insulin-treated type 2 diabetes: under 30 U/day insulin, metformin was associated with fewer adverse neonatal outcomes (44% v 55%; aRR 0.76); no difference above 60 U/day.
Secondary analysisn = 785 women
Shrestha et al. The effect of metformin on perinatal outcomes in pregnant women with type 2 diabetes differs by baseline insulin requirements